These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

825 related items for PubMed ID: 16675560

  • 1. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T, Matsui M, Torigoe T, Sato N, Baba H, Nishimura Y.
    Clin Cancer Res; 2006 May 01; 12(9):2689-97. PubMed ID: 16675560
    [Abstract] [Full Text] [Related]

  • 2. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y, Nakatsura T, Senju S.
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct 01; 31(5):383-91. PubMed ID: 18974622
    [Abstract] [Full Text] [Related]

  • 3. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
    Komori H, Nakatsura T, Beppu T, Nishimura Y, Baba H.
    Gan To Kagaku Ryoho; 2006 Nov 01; 33(12):1742-4. PubMed ID: 17212093
    [Abstract] [Full Text] [Related]

  • 4. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y, Ikuta Y, Kuronuma T, Komori H, Ito M, Tsuchihara M, Tsunoda Y, Shirakawa H, Baba H, Nishimura Y, Kinoshita T, Nakatsura T.
    Int J Oncol; 2008 May 01; 32(5):985-90. PubMed ID: 18425324
    [Abstract] [Full Text] [Related]

  • 5. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
    Nobuoka D, Motomura Y, Shirakawa H, Yoshikawa T, Kuronuma T, Takahashi M, Nakachi K, Ishii H, Furuse J, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kinoshita T, Komori H, Baba H, Fujiwara T, Nakatsura T.
    Int J Oncol; 2012 Jan 01; 40(1):63-70. PubMed ID: 21922136
    [Abstract] [Full Text] [Related]

  • 6. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T, Komori H, Kubo T, Yoshitake Y, Senju S, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y.
    Clin Cancer Res; 2004 Dec 15; 10(24):8630-40. PubMed ID: 15623647
    [Abstract] [Full Text] [Related]

  • 7. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y.
    Clin Cancer Res; 2008 Oct 15; 14(20):6487-95. PubMed ID: 18927288
    [Abstract] [Full Text] [Related]

  • 8. Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.
    Mizukoshi E, Nakamoto Y, Marukawa Y, Arai K, Yamashita T, Tsuji H, Kuzushima K, Takiguchi M, Kaneko S.
    Hepatology; 2006 Jun 15; 43(6):1284-94. PubMed ID: 16729333
    [Abstract] [Full Text] [Related]

  • 9. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
    Yoshikawa T, Nakatsugawa M, Suzuki S, Shirakawa H, Nobuoka D, Sakemura N, Motomura Y, Tanaka Y, Hayashi S, Nakatsura T.
    Cancer Sci; 2011 May 15; 102(5):918-25. PubMed ID: 21281401
    [Abstract] [Full Text] [Related]

  • 10. Efficient induction of cytotoxic T lymphocytes specific to hepatocellular carcinoma using HLA-A2-restricted MAGE-n peptide in vitro.
    Dong HL, Sui YF, Li ZS, Qu P, Wu W, Ye J, Zhang XM, Lu SY.
    Cancer Lett; 2004 Aug 10; 211(2):219-25. PubMed ID: 15219945
    [Abstract] [Full Text] [Related]

  • 11. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K, Teramoto K, Ozaki Y, Fujita T, Tezuka N, Sawai S, Watanabe H, Fujino S, Yokomise H, Ohkubo I.
    Int J Oncol; 2004 Dec 10; 25(6):1537-42. PubMed ID: 15547688
    [Abstract] [Full Text] [Related]

  • 12. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S, Azuma K, Komatsu N, Ito M, Maeda Y, Ishihara Y, Itoh K.
    Clin Cancer Res; 2004 Sep 01; 10(17):5828-36. PubMed ID: 15355913
    [Abstract] [Full Text] [Related]

  • 13. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
    Suzuki S, Yoshikawa T, Hirosawa T, Shibata K, Kikkawa F, Akatsuka Y, Nakatsura T.
    Cancer Sci; 2011 Sep 01; 102(9):1622-9. PubMed ID: 21668581
    [Abstract] [Full Text] [Related]

  • 14. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro.
    Fujie T, Tanaka F, Mori M, Takesako K, Sugimachi K, Akiyoshi T.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2425-30. PubMed ID: 9815643
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line coexpressing HLA-A2/H-2kb and CTL multiepitope in HLA transgenic mice.
    Song S, Wang F, He X, He Y, Li D, Sun S.
    Vaccine; 2007 Jun 15; 25(25):4853-60. PubMed ID: 17418455
    [Abstract] [Full Text] [Related]

  • 16. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, DeLeo AB.
    Clin Cancer Res; 2000 Mar 15; 6(3):979-86. PubMed ID: 10741724
    [Abstract] [Full Text] [Related]

  • 17. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes.
    Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF.
    J Immunol; 1995 Aug 01; 155(3):1343-8. PubMed ID: 7543520
    [Abstract] [Full Text] [Related]

  • 18. T Cells Engineered to Express a T-Cell Receptor Specific for Glypican-3 to Recognize and Kill Hepatoma Cells In Vitro and in Mice.
    Dargel C, Bassani-Sternberg M, Hasreiter J, Zani F, Bockmann JH, Thiele F, Bohne F, Wisskirchen K, Wilde S, Sprinzl MF, Schendel DJ, Krackhardt AM, Uckert W, Wohlleber D, Schiemann M, Stemmer K, Heikenwälder M, Busch DH, Richter G, Mann M, Protzer U.
    Gastroenterology; 2015 Oct 01; 149(4):1042-52. PubMed ID: 26052074
    [Abstract] [Full Text] [Related]

  • 19. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
    Homma S, Harada M, Yano H, Ogasawara S, Shichijo S, Matsueda S, Komatsu N, Shomura H, Maeda Y, Sato Y, Todo S, Itoh K.
    Int J Oncol; 2006 Sep 01; 29(3):577-87. PubMed ID: 16865273
    [Abstract] [Full Text] [Related]

  • 20. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A, Paz A, Bar Haim E, Goldberger O, Finkel E, Tirosh B, Volovitz I, Vadai E, Lugassy G, Cytron S, Lemonnier F, Tzehoval E, Eisenbach L.
    Cancer Res; 2005 Jul 15; 65(14):6435-42. PubMed ID: 16024648
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.